Skip to main content

Table 2 Randomly selected consecutive HER2+ cases by traditional FISH criteria

From: Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay

Patient no.

Histology

Grade

ER/PR

HER2 IHCa

HER2 copies

HER2/CEP17 ratio

Intrinsic subtype

TNM stage

Herceptin ± chemo given?

NAT, AT, MET

Herceptin ± chemo regimenb

If NAT, pathologic response?

Follow-up timec

Disease status

1

IDC

3

+/+

+ 3

19.1

5.8

NS

pT1cN0

No; patient declined

N/A

N/A

N/A

9 months

Remission

2

IMPC

2

−/−

+ 3

17.6

4.8

NS

pT1bNx

No; not offered 2/2 age/comorbidities

N/A

N/A

N/A

4 months

Died of AAA rupture

3

IDC

3

+/+

+ 3

20.6

6.6

Luminal A

cT2N1M0

Yes

NAT & AT

NAT: T-DM1 + P on a trial, AT: THP

PR

25 months

Remission

4

IDC

3

+/+

+ 3

> 10

5.2

HER2-E

cT1cN0

Yes

NAT & AT

NAT: T-DM1 + P on a trial, then AT: docetaxel ×4 cycles + H ×1 year

CR

12 months

Remission

5

IDC

3

−/−

+ 3

> 20

1.0d

HER2-E

cT1cN0

Yes

NAT

THP

CR

18 months

Remission

6

IDC

2

−/−

+ 3

12.8

5.4

NS

cT2-3 N1

Yes

NAT

THP-ddAC

PR

5 months

Remission

7

IDC

3

−/−

+ 3

23.3

5.3

HER2-E

cT2N0

na

na

Na

na

na

na

8

IDC

3

−/−

+ 3

20.7

6.4

NS

pT1cNx

Yes

AT

TH

N/A

27 months

Remission

9

ILC

2

−/−

+ 3

> 6

5.6

NS

pT1aN0

Yes

AT

TH

N/A

25 months

Remission

10

IDC

3

−/−

+ 3

26.3

7.6

HER2-E

pT1bN0

Yes

AT

TH

N/A

30 months

Remission

11

IDC

3

−/−

+ 3

> 10

> 3.8

HER2-E

pT1bN0

Yes

AT

TH

N/A

21 months

Remission

12

IMPC

3

−/−

+ 3

19.85

7.4

HER2-E

pT1cN1a

Yes

AT

ddAC-TH

N/A

28 months

Remission

13

IDC

2

+/−

+ 3

37.2

6.8

NS

pT1bN0

Yes

AT

ddAC-TH

N/A

26 months

Remission

14

IDC

3

+/−

+ 3

6.88

3.2

NS

pT2N1a

Yes

AT

THP ×12 weeks, ddACX2 (stopped 2/2 SAE, 1 year H)

N/A

22 months

Remission

15

IDC

3

+/−

+ 3

> 20

9.5

NS

pT1aN0

Yes

AT

T-DM1 on a trial

N/A

20 months

Remission

16

IDC

3

+/−

+ 3

23

8.1

HER2-E

pT1bN1a

Yes

AT

ddAC-THP

N/A

17 months

Remission

17

IDC

3

+/+

+ 3

> 10

3

NS

T2N1M1b

Yes

MET

THP, AC, various

N/A

35 months

Alive, on tx

18

IDC

3

−/−

+ 3

26.7

9.4

HER2-E

na

na

na

na

na

na

na

19

IDC

2

+/−

+ 3

20.3

3.4

NS

cT3N1

na

na

na

na

na

na

  1. aHER2 IHC: 0–1+ is negative, 2+ is equivocal, 3+ is positive
  2. bAll patients who received trastuzumab-based treatment received trastuzumab (H) for 1 year unless otherwise specified
  3. cFollow up time defined as time in months from date of initial breast biopsy to date of last clinical follow-up
  4. d HER2 ratio 1.0 because HER2 copies and CEP 17 copies both > 20, so HER2 alternative probe ratio performed to confirm HER2 status
  5. AC Adriamycin + cyclophosphamide, AT adjuvant therapy, CR complete response, ddAC dose-dense adriamycin + cyclophosphamide, ER estrogen receptor, FISH fluorescence in-situ hybridization, H herceptin (trastuzumab), HER2 human epidermal growth factor receptor 2, HER2-E HER2-enriched, IDC invasive ductal cancer, IHC immunohistochemistry, ILC invasive lobular cancer, IMPC invasive micropapillary cancer, MET therapy for metastatic disease, N/A not applicable, na not available, NAT neoadjuvant therapy, NS not sufficient for testing, P pertuzumab, PR partial response, PR progesterone receptor, T weekly paclitaxel ×12, T-DM1 ado-trastuzumab, TNM tumor node metastasis, Tx therapy